Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Delta Air Lines, Inc. (DAL) vs Pfizer Inc (PFE) Price & Performance

Delta Air Lines, Inc.Trade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Delta Air Lines, Inc. vs Pfizer Inc — how do they compare? Delta Air Lines, Inc. trades at $85.92 (market cap $56.68B), while Pfizer Inc trades at $24.28 (market cap $139.52B). The key difference: Pfizer Inc is far larger — about 2.5× Delta Air Lines, Inc.'s market cap, and Pfizer Inc pays the higher dividend (7.03%). Which is the better fit depends on your goals.

DALPFE
Market Cap
$56.68B$139.52B
Sector
IndustrialsHealth
52-Week High
$93.66$28.56
52-Week Low
$51.15$23.29
Enterprise Value
$72.00B$190.18B
Dividend Yield
0.9%7.03%
Volume
29,869,932

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Delta Air Lines, Inc.

Delta Air Lines (DAL) trades at $86.19, down 1.37% on the day, with a bullish technical outlook supported by strong earnings beats and positive analyst sentiment. The stock shows solid fundamentals with a P/E of 14.29 and net income margin of 5.78%, while recent news highlights premium demand resilience and AI-driven customer satisfaction improvements. Cash flow trends have strengthened, with net cash flow turning positive in 2025 at $1.08 billion.

The outlook remains favorable with an 81.82% analyst buy rating and a $108.27 consensus price target implying 26% upside. Key risks include fuel cost volatility and competitive pressures, but strong institutional support and consistent earnings performance underpin potential for continued growth amid stable travel demand.

Pfizer Inc

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Delta Air Lines, Inc.

Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.

Read more on DAL

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE